scholarly journals BONE DENSITY PARAMETERS CHANGING IN POSTMENOPAUSAL WOMEN WITH DIFFUSE SITES NONTOXIC GOITER AND AUTOIMMUNE THYROIDITIS IN TREATMENTLOW-DOSE ESTROGEN-PROGESTOGENS MEDICATION

2015 ◽  
Vol 7 (3) ◽  
pp. 38-43
Author(s):  
V A Gromova ◽  
N V Vorokhobina ◽  
O F Malygina ◽  
A V Kuznetsova
Keyword(s):  
Autoimmune Thyroiditis ◽  
Low Dose ◽  
Bone Structure ◽  
Hormone Replacement ◽  
Control Group ◽  
Endocrine Glands ◽  
Mineral Density ◽  
X Ray ◽  
Nontoxic Goiter ◽  
Reliable Increase

Postmenopausal osteoporosis - multifactorial disease, on the pathogenesis of which affect not only the estrogen deficiency, but functional state of other endocrine glands, particularly the thyroid gland. The article presents the results of a research 74 women with autoimmune thyroiditis and diffuse nodular nontoxic goiter, which during perimenopause and menopause for 12 months received low-dose estrogen-progestin preparation containing 2 mg drospirenone and 1 mg of 17-estradiol. The control group consisted of 40 women of similar age without thyroid disease who were not receiving drugs hormone replacement therapy (HRT). To study the effect of HRT on bone metabolism all women at baseline and after 12 months of follow-conducted study of bone mineral density (BMD) with dual en ergy X-ray absorptiometry (DXA). As a result of the treatment received reliable increase in BMD in the lumbar spine L1-L4 9-10% (p <0.001) in the proximal femur - by 2.8-3.5% (p <0.01) in the bones forearm - by 1.8-2.1% (p <0.01).Conclusion: The use of low-dose estrogen-progestin drugs for 12 months in women with autoimmune thyroiditis and diffuse nodular nontoxic goiter in peri- and postmenopausal period helped gain in BMD in both trabecular and cortical bone structure.

scholarly journals EFFICIENCY OF THE LOW-DOSE FORMS ESTROGEN-GESTAGEN DRUG TREATMENTTO WOMEN WITH COMPENSATED HYPOTHERIOSIS AND EUTHYROIDISM

2015 ◽  
Vol 7 (1) ◽  
pp. 40-45
Author(s):  
V A Gromova ◽  
N V Vorokhobina ◽  
O F Malygina ◽  
A V Kuznetsova
Keyword(s):  
Hormone Replacement Therapy ◽  
Lipid Profile ◽  
Replacement Therapy ◽  
Autoimmune Thyroiditis ◽  
Thyroid Disease ◽  
Low Dose ◽  
Hormone Replacement ◽  
Thyroid Status ◽  
Nontoxic Goiter ◽  
Progestin Therapy

The article presents research results of 61 perimenopausal and postmenopausal women with diffuse nodular nontoxic goiter and autoimmune thyroiditis, who in the 12 months received treatment low-dose combined estrogen-progestin drug, which includes a 1 mg 17-β estradiol and 2 mg drospirenone. The effect of hormone replacement therapy on coagulation and platelet hemostasis, lipid profile, pituitary-ovarian system, thyroid status were studied. Using of low-dose estrogen-progestin therapy does not worsen diffuse nodular nontoxic goiter and autoimmune thyroiditis flow, does not change the dose of thyroid medications and may be recommended for the treatment of menopausal symptoms in women with thyroid disease.

scholarly journals Evaluation of the BDNF, NGF, NT3 and NT4 Genes Expressions in the Brains of Neonatal Mice with Hypothyroidism

2017 ◽  
Vol 7 (1) ◽  
pp. 171
Author(s):  
Hamid Reza Adeli Bhroz ◽  
Kazem Parivar ◽  
Iraj Amiri ◽  
Nasim Hayati Roodbari
Keyword(s):  
Dose Group ◽  
Low Dose ◽  
Pure Water ◽  
Intervention Group ◽  
Control Group ◽  
High Dose ◽  
Endocrine Glands ◽  
Blood Samples ◽  
High Doses ◽  
The Brain

Background and Aim: Thyroid is one of the endocrine glands, (T3 and T4) play a significant role in the development of prenatal brain and the following stages. The study aimed to evaluate the effect of hypothyroidism on the amount of expression of NT4, NT3, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in brain of one-day rat neonates with hypothyroidism.Materials and Methods: In total, 25 mature mice of Albino NMRI race were selected after mating, divided into three group, control, as well as low-dose and high-dose intervention groups. Samples of the control group received pure water during pregnancy, whereas subjects of the intervention group with low and high doses of the medication were administered with 20 mg and 100 mg methimazole powder (dissolved in 100 cc water), respectively. After child delivery, blood samples were obtained from mother mice to determine the level of T3 and T4 in blood serum. Following that, the brain of one-day mice were removed by surgery and assessed to determine the amount of expression of NT4, NT3, NGF and BDNF using the complete kit of RT-PCR.Results: Levels of T4 and T3 in the control group were 28 ug/dl and 1.59 ug/dl, respectively. In the low-dose intervention group, the amounts of the mentioned hormones were 8 ug/dl and 0.85 ug/dl, significantly, indicating a significant reduction in the expression of NT4, NT3, NGF and BDNF genes, compared to the control group. Moreover, T4 and T3 were 6 ug/dl and 0.79 ug/dl in the high-dose group, respectively, conveying a significant decrease in the expression of NT4, NT3, NGF and BDNF genes, compared to the control group (P<0.05).

CTRP3 is Significantly Decreased in Patients with Primary Hyperparathyroidism and Closely Related with Osteoporosis

2019 ◽  
Vol 128 (03) ◽  
pp. 152-157
Author(s):  
Derya Demirtas ◽  
Fettah Acıbucu ◽  
Filiz Alkan Baylan ◽  
Erdinc Gulumsek ◽  
Tayyibe Saler
Keyword(s):  
Primary Hyperparathyroidism ◽  
Serum Levels ◽  
Dual Energy ◽  
Control Group ◽  
Mineral Density ◽  
Urine Calcium ◽  
X Ray ◽  
Complement C1q ◽  
Necrosis Factor

Abstract Background Adipokines derived from adipocytes are one of the important factors that act as circulating regulators of bone metabolism. Complement C1q/tumor necrosis factor-related protein-3 (CTRP3), a paralog of adiponectin, is are member of the CTRP superfamily. The aim of this study was to investigate the role of serum CTRP3 in the development of osteoporosis in patients with primary hyperparathyroidism. Methods This study included 53 patients with diagnosed primary hyperparathyroidism and 30 healthy controls. Laboratory tests for the diagnosis of primary hyperparathyroidism and serum levels of CTRP3 measured for all patients. Bone mineral density was obtained on lumbar spine 1 and 4 by dual energy X-ray absorptiometry. Results Serum CTRP3 levels were lower in patients with primary hyperparathyroidism than in the control group (p<0.001). In addition, primary hyperparathyroidism patients are were divided into two groups as, with and without osteoporosis; the levels of CTRP3 were lower in patients with osteoporosis than in patients without osteoporosis (p=0.004). In logistic regression analysis, only CTRP3 levels independently determined the patients to be osteoporosis (p<0.05). According to this analysis, decreased CTRP3 (per 1 ng/mL) levels were found to increase the risk of patients for osteoporosis by 6.9%. When the CTRP3 cut-off values were taken as 30 ng/mL, it determined osteoporosis with 76.4% sensitivity and 73.2% specificity. CTRP3 and urine calcium levels were independently associated with T score in dual energy X-ray absorptiometry. Conclusions CTRP3 levels were significantly decreased in patients with primary hyperparathyroidism, and it is also related to osteoporosis.

Comparative Study of Low Dose Conjugate Equine Estrogen 0.3 mg vs Standard Dose Conjugate Equine Estrogen 0.625 mg as Hormone Replacement Therapy

2013 ◽  
Vol 1 (2) ◽  
pp. 45-49
Author(s):  
Meeta Gupta ◽  
Poonam Yadav ◽  
Sarvesh Kumar
Keyword(s):  
Hormone Replacement Therapy ◽  
Comparative Study ◽  
Replacement Therapy ◽  
Low Dose ◽  
Standard Dose ◽  
Hormone Replacement ◽  
Mineral Density ◽  
Conjugate Equine Estrogen ◽  
Group A ◽  
Group B

ABSTRACT Introduction Since menopause was related to variety of genitourinary, vasomotor, psychological and musculoskeletal changes, conjugated equine estrogen (CEE) was introduced for all menopause-related symptoms in various doses. Materials and methods It is a comparative study in which 100 postmenopausal women were selected (natural or surgical menopause) with one or more menopausal symptoms. All patients were randomly divided in two groups. Group A received 0.3 mg CEE and group B received 0.625 mg CEE, and both groups were compared with each other in various aspects. Results Both the groups were comparable to each other with respect to mean age, residence, type of menopause, total duration of menopause. Both the groups show comparable improvement in vasomotor, genitourinary and psychological symptoms and p > 0.05 which is not significant. On evaluation of bone mineral density (BMD), the group B showed significant improvement than group A (p < 0.001). Effect on endometrium was not significant. Conclusion Because of the complications of estrogen ± progestin, it should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risk for individual women. How to cite this article Yadav P, Singh R, Kaur H, Gupta M, Kumar S. Comparative Study of Low Dose Conjugate Equine Estrogen 0.3 mg vs Standard Dose Conjugate Equine Estrogen 0.625 mg as Hormone Replacement Therapy. J South Asian Feder Menopause Soc 2013;1(2):45-49.

Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausal women

1999 ◽  
Vol 96 (4) ◽  
pp. 357-364 ◽  
Author(s):  
D. A. SKELTON ◽  
S. K. PHILLIPS ◽  
S. A. BRUCE ◽  
C. H. NAYLOR ◽  
R. C. WOLEDGE
Keyword(s):  
Bone Mineral Density ◽  
Muscle Strength ◽  
Bone Mineral ◽  
Hormone Replacement ◽  
Treated Group ◽  
Control Group ◽  
Sectional Area ◽  
Mineral Density ◽  
Cross Sectional ◽  
Post Menopausal

A randomized open trial of hormone replacement therapy was used to assess changes in adductor pollicis muscle strength during 6–12 months of treatment with Prempak C 0.625® in comparison with an untreated control group. Muscle strength (maximal voluntary force; MVF), muscle cross-sectional area and bone mineral density were measured. Women entering the trial had oestrogen levels below 150 pmolċl-1, confirming their post-menopausal hormonal status. In the treated group, MVF increased by 12.4±1.0% (mean±S.E.M.) of initial MVF over the duration of treatment, while it declined slightly (2.9±0.9%) in the control group. This increase in strength could not be explained by an increase in muscle bulk, there being no significant increase in cross-sectional area during the study. Those subjects who were weakest at enrolment showed the greatest increases in muscle strength after treatment. Bone mineral density in total hip, Ward's triangle and total spine increased in the treated group, in agreement with previous studies. There was no correlation between the individual increases in bone mineral density and those in MVF.

scholarly journals Bone changes during and after treatment of childhood acute lymphoblastic leukaemia

2021 ◽  
Vol 20 (1) ◽  
pp. 54-57
Author(s):  
S. Ragab ◽  
B. Montaser ◽  
N. El-Ashmawy ◽  
M. El-Hawy
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Normal Population ◽  
Serum Insulin ◽  
Lymphoblastic Leukemia ◽  
Dual Energy ◽  
Anthropometric Measurement ◽  
Control Group ◽  
Mineral Density ◽  
Childhood All ◽  
X Ray

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with a survival rate of 80%. Major complications of leukemia include osteoporosis that requires both a clinically significant fracture history and low bone mineral density (BMD). The present study aims to assess BMD among acute lymphoblastic leukemia patients and survivors using dual-energy x-ray absorptiometry and serum insulin growth factor binding protein 3. The study was approved by the Independent Ethics Committee and the Scientific Council of the Menoufia University, Egypt. Thirty patients with ALL and thirty survivors who were diagnosed with ALL but completely recovered were enrolled in this study. Sex and age matched normal controls while full history was taken. Patients and survivors were examined for anthropometric measurement. Laboratory including serum IGFBP3and dual-energy x-ray absorptiometry was done for all. It has been found out that patients and survivors showed a markedly lower BMD than normal population but no history of fracture was found in survivors. In this study, the prevalence of low BMD is 26/30 (86.6%) patients and 25/30 (83.3%) survivors. Also, there was a statistically significant decrease of DEXA scan measures in patients and survivors groups than the control group with a statistically significant decrease in both BMD and Z- score measures in patients and survivors groups than control group. Patients and long-term survivors of childhood ALL are at risk for morbidity associated with low BMD. They may benefit from interventions to optimize bone health as they age. 

scholarly journals SAT-395 Correlations Between Biochemical Parameters and Trabecular Bone Score (TBS) in Primary Hyperparathyroidism (PHP) Patients

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Lívia Marcela Santos ◽  
Monique Nakayama Ohe ◽  
Sthefanie Giovanna Pallone ◽  
Ilda Sizue Kunii ◽  
Renata Elen Costa Silva ◽  
...  
Keyword(s):  
Vitamin D ◽  
Trabecular Bone ◽  
Vitamin D Deficiency ◽  
Negative Correlation ◽  
Bone Structure ◽  
Trabecular Bone Score ◽  
Control Group ◽  
Total Calcium ◽  
Mineral Density ◽  
Positive Correlation

Abstract Background: Vitamin D deficiency is common among PHP patients. While data are limited, some studies suggest that vitamin D deficiency may exacerbates skeletal disease in PHP. TBS is a software-based method for assessment of trabecular bone structure of the spine, based on analysis of pixels obtained in dual energy x-ray absorptiometry (DXA) images. The aim of this study was to evaluate TBS, vitamin D status, clinical and laboratorial measurements in a PHP group of patients in a search for a more accurate bone fragility test for risk assessment in this group of patients. Methods: From June/2017 to January/2019, patients who met the criteria for PHP diagnosis were included in this study. Control group was composed by age and sex-matched healthy individuals. Overall, 64 PHP and 63 controls were enrolled. Bone mineral density (BMD) measured by DXA (Hologic QDR 4500) at the lumbar spine, total hip, femoral neck, and TBS values (InSight™) were determined in both groups. Total and ionized calcium, PTH, 25-hydroxyvitamin D (25(OH)D), creatinine, alkaline phosphatase, P1NP and CTX were measured. None were in use of Vitamin D supplementation. Results: As expected, PHP patients had lower BMD values than controls in all sites (p&lt;0.0001). TBS measurements were also reduced in PHP patients compared to controls (1233 vs 1280, p=0.0444). TBS values were inversely correlated with total calcium (CaT) and phosphorus measurements were positively correlated in the PHP patients. 25(OH)D measurements didn’t differ between groups (PHP 22.5 vs. controls 19.8 ng/mL, p=0.1699). There was a positive correlation between 25(OH)D and TBS in both PHP and controls (r= 0,3088, p= 0,0138 and r= 0,3708, p= 0,003 respectively). Considering individuals with vitamin D deficiency (25(OH)D levels &lt;=20 ng/mL), a negative correlation between TBS and CaT measurements among PHP patients (r= -0,4391, p=0,0172) was observeed, while in controls there was a positive correlation between TBS and 25(OH)D (r= 0,3504, p= 0,0362). Conclusion: Serum total calcium presents negative correlation and phosphorus a positive one with TBS in PHP patients. We also found a correlation between TBS and 25(OH)D, both in PHP and in controls. 25(OH)D &lt;=20 ng/mL is an independent risk factor determining degraded TBS among PHP patients and controls.

Sign in / Sign up

Export Citation Format

Share Document